Transforming clinical trials, Suvoda has secured $40 million for the continued growth and the expansion of its product offerings.
FREMONT, CA: A SaaS provider of clinical trial software, Suvoda has bagged a $40 million minority equity investment from LLR Partners, which is a Philadelphia-based private equity firm. LLR's investment is an innovative institutional capital invested in Suvoda that will be used to help in supporting the company's continued growth and the expansion of its product offerings. Suvoda provides a robust SaaS solution that helps pharmaceutical and biotechnology companies manage intricate trial designs. The company assists in optimizing the supply chain across the clinical trial continuum, from small investigator-sponsored trials to significant global Phase III studies.
Suvoda has grown into a multi-national organization in the U.S. and Europe, serving customers and end-users in 62 countries. The company is thrilled to have collaborated with LLR Partners, moving towards growth. The SaaS provider of clinical trial software is focused on transforming clinical trials using the power of technology. The company's Interactive Response Technology (IRT) system solves complex patient randomization and clinical trial supply chain challenges. This round of investment will focus on enhancing best-in-class functionality, enabling users to expect the unexpected in their clinical program confidently.
Suvoda is an innovative SaaS firm centered on transforming clinical trials using the power of technology. The company solves complex patient randomization and clinical supply chain challenges. Suvoda's IRT system with Trial Intelligence offers speed, agility, and insight to handle the most complex clinical trials with ease. Its Drug Inventory Management System (DIMS) is designed for supply chain and inventory management for more straightforward trials that do not require patient management.